Ipsos Launches Immuno-Oncology Mental Mapping Study

Ipsos has launched its Immuno-Oncology (I-O) Mental Mapping Study in China.

 

Ipsos has launched its Immuno-Oncology (I-O) Mental Mapping Study in China, with other countries in development. The new syndicated study – which leverages Ipsos’ proprietary analytics tool, EquityVision – provides an in-depth perceptual view of the classes, products and companies active within the I-O space. 

Specifically, the I-O Mental Mapping Study will reveal oncologists’ awareness of I-O products, their current and future usage and their perceptions of manufacturers, access and affordability. Meanwhile, the EquityVision mental mapping component will uncover how oncologists and other cancer-treating specialists truly perceive different brands. Subscribers to the study will be able to understand both the differentiation of their product and its likely future uptake within the competitive landscape. The study is currently running in three Tier I and eight Tier 2 cities in China and will be rolled out to other countries in 2019.

Commented Pieter De Richter, Head of Ipsos’ Real World Evidence Portfolio in Asia Pacific, Middle East and North Africa: 

“2018 marked the launch of two immune checkpoint inhibitors in China, with many more in the pipeline; indeed, multinational pharma companies as well as domestic biotechs are targeting China as a key market for driving PD-1 and PD-L1 inhibitor uptake.  How oncologists perceive and choose between these highly similar I-O brands is difficult to ascertain using traditional research methods. The new study will help us to understand what is truly salient to physicians and how to put a brand story into its competitive context. Furthermore, the study covers awareness and predicted usage of other emerging I-O therapies that are on the horizon in China, such as the CAR-T class.”

Contact:
•    Pieter De Richter, Head of Real World Evidence in Asia Pacific, Middle East & North Africa
Tel: +603 2297 5628; Email: [email protected]

•    Joanna Butcher, Syndicated Marketing Communications Director, Ipsos  
Tel: +44 (0)7818 422117; Email: [email protected]